Bulitta jb

Author: vzjc

August undefined, 2024

Web25 May 2024 · Bulitta JB, Ly NS, Yang JC, Forrest A, Jusko WJ, Tsuji BT. 2009. Development and qualification of a pharmacodynamic model for the pronounced … Web1 Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, 6550 Sanger Road, Office 475, Orlando, FL, …

Bulitta Research Lab - University of Florida

Web23 Feb 2024 · Bulitta JB, 0000-0001-7352-3097, University of Florida Li J, 0000-0001-7953-8230 Lenhard JR, 0000-0002-2570-7593, California Northstate University College of Pharmacy Bulman ZP, 0000-0002-5396-911X, University of Illinois at Chicago Antimicrobial Agents and Chemotherapy , 23 Feb 2024, 61 (3): e01268-16 inc. rate

Supplementary Pharmacokinetic Validation Final (002)

Web27 Mar 2024 · Bulitta JB, 0000-0001-7352-3097, University of Florida; Oliver A, 0000-0001-9327-1894; Boyce JD, 0000-0002-8614-3074 ... John D. Boyce, Jürgen B. Bulitta, … http://www.sciepub.com/reference/376198 Web1 Mar 2024 · Cheah SE, Li J, Tsuji BT, Forrest A, Bulitta JB, Nation RL. Colistin and polymyxin B dosage regimens against Acinetobacter baumannii: differences in activity and the emergence of resistance. Antimicrob Agents Chemother. 2016;60(7):3921-3933. Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS. Polymyxin B and colistimethate are … inc. publication

Yadav R, Bulitta JB, Wang J, Nation RL, Landersdorfer CB.

Resurgence of colistin: a review of resistance, toxicity ...

WebCeftazidime/Avibactam (CAZ/AVI) is a β-lactam/β-lactamase inhibitor combination with activity against type A and C β-lactamases. Resistance emergence has been seen with multiple mechanisms accounting for the resistance. We performed four experiments in the dynamic Hollow Fiber Infection Model, delin … WebHigh-performance liquid chromatography (HPLC) was used for drug analysis, and NONMEM (results reported), S-ADAPT, and NPAG were used for parametric and nonparametric … include with colonWeb1 Dec 2010 · Bulitta JB, Tsuji BT Author information Affiliations 1 author 1. Laboratory for Antimicrobial Pharmacodynamics, School of Pharmacy and Pharmaceutical Sciences … include with device

"WebDr. Bulitta is collaborating with experts in animal infection models, antibiotic drug development, bacterial resistance mechanisms and genetics, transcriptomics, … " - Bulitta jb

Bulitta jb

Colistin and Polymyxin B Dosage Regimens against …

WebDr. Bulitta has a long-standing interest in beta-lactam antibiotics which are the largest and most commonly used group of antibiotics. These drugs can be used safely in patients of … WebBeta-lactams are regularly administered in intermittent short-term infusions. The percentage of the dosing interval during which free drug concentrations exceed the MIC (fT(>MIC)) is …

Did you know?

WebLy NS, Yang JC, Bulitta JB, Tsuji B. Impact of two-component regulatory systems PhoP-PhoQ and PmrA-PmrB on colistin pharmacodynamics in Pseudomonas aeruginosa. … WebYadav R, Bulitta JB, Wang J, Nation RL, Landersdorfer CB. Evaluation of pharmacokinetic/pharmacodynamic model-based optimized combination regimens …

WebAssistant Professor, College of Pharmacy - Pharmacy Practice Contact Office Phone: (312) 996-1415 (work) Email: [email protected] Related Sites: ORCID View Full Profile Website About Research Interests: WebThe pharmacokinetics (PK) of β-lactam antibiotics in cystic fibrosis (CF) patients has been compared with that in healthy volunteers for over four decades; however, no quantitative models exist that explain the PK differences between CF patients and healthy volunteers in older and newer studies. Our …

WebBulitta JB, Jiao Y, Landersdorfer CB, Sutaria DS, Tao X, Shin E et al. Comparable bioavailability and disposition of pefloxacin in patients with cystic fibrosis and healthy … Web1 Jan 2009 · Bulitta JB, 0000-0001-7352-3097, University of Florida Holzgrabe U, 0000-0002-0364-7278, University of Kiel Landersdorfer CB, 0000-0003-0928-4743, Monash University (Parkville Campus) Clinical Pharmacokinetics , 01 Jan 2009, 48 (2): 89-124 DOI: 10.2165/00003088-200948020-00002 PMID: 19271782 Review

Web4 Mar 2024 · Corpus ID: 73461960 Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans J. Bulitta, W. Hope, +5 authors J. Hoover Published 4 March 2024 Medicine, Biology Antimicrobial Agents and Chemotherapy

Web24 Apr 2024 · Bulitta JB, 0000-0001-7352-3097, University of Florida Wallis SC, 0000-0002-2392-9854, University of Queensland Kirkpatrick CMJ, 0000-0002-5715-1534, Monash … include with select linqWebJürgen Bernd Bulitta, Ph.D. Since July 2024 Full Professor (tenured), Department of Pharmacotherapy and Translational Research (PTR), College of Pharmacy (COP), … include with where sequelizeWeb19 Jun 2024 · Methodology: A 3-min run of LC–MS/MS method was established to determine the main components of polymyxin B (polymyxin B1 and B2) in human plasma or urine. Solid-phase extraction was employed to eliminate the matrix effect from complicated samples from patients. inc. purses